What this covers
Metachromatic leukodystrophy (MLD) is a rare inherited lysosomal storage disorder caused by a deficiency of the enzyme arylsulfatase A, which leads to a build-up of toxic sulfatide and progressive damage to the nervous system. Because treatments such as stem cell transplantation and gene therapy work best before symptoms appear, newborn screening has become feasible and important — but there has been little guidance on what to do once a baby is identified. This project brought international MLD experts and patient advocates together to agree on how such cases should be monitored and managed.
Key takeaways
- Using a structured consensus method, 22 experts and patient representatives agreed on 57 statements to guide the care of babies identified with MLD through newborn screening.
- Key recommendations include prompt communication with affected families, treating early-onset disease with gene therapy and late-onset disease with stem cell transplantation, and following agreed pre-treatment monitoring schemes.
- The group also identified specific gaps in knowledge and called for prioritised research to support future evidence-based guidelines.
Why it matters
Agreed recommendations give clinicians a shared, practical framework for managing newborn-screened MLD, helping ensure that identified children receive timely, consistent care as screening is rolled out.
